MA30345B1 - ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY FORMULATION - Google Patents

ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY FORMULATION

Info

Publication number
MA30345B1
MA30345B1 MA31308A MA31308A MA30345B1 MA 30345 B1 MA30345 B1 MA 30345B1 MA 31308 A MA31308 A MA 31308A MA 31308 A MA31308 A MA 31308A MA 30345 B1 MA30345 B1 MA 30345B1
Authority
MA
Morocco
Prior art keywords
igf
monoclonal antibody
human monoclonal
antibody formulation
formulation
Prior art date
Application number
MA31308A
Other languages
French (fr)
Inventor
Adelbert Grossmann
Hanns-Christian Mahler
Astrid Pappenberger
Oliver Boris Stauch
Jan Olaf Stracke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA30345B1 publication Critical patent/MA30345B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne une formulation d'anticorps monoclonal humain anti-IGF-1R, un procédé pour la préparation et les utilisations de celle-ci.The present invention relates to an anti-IGF-1R human monoclonal antibody formulation, a process for the preparation and uses thereof.

MA31308A 2006-03-28 2008-10-20 ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY FORMULATION MA30345B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28

Publications (1)

Publication Number Publication Date
MA30345B1 true MA30345B1 (en) 2009-04-01

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31308A MA30345B1 (en) 2006-03-28 2008-10-20 ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY FORMULATION

Country Status (18)

Country Link
EP (1) EP1998806A1 (en)
JP (1) JP2009531371A (en)
KR (1) KR20080104160A (en)
CN (1) CN101410137A (en)
AR (1) AR060130A1 (en)
AU (1) AU2007229554A1 (en)
BR (1) BRPI0709229A2 (en)
CA (1) CA2647111A1 (en)
CL (1) CL2007000797A1 (en)
CR (1) CR10295A (en)
EC (1) ECSP088778A (en)
IL (1) IL193904A0 (en)
MA (1) MA30345B1 (en)
MX (1) MX2008012295A (en)
NO (1) NO20083895L (en)
RU (1) RU2008142359A (en)
TW (1) TW200815029A (en)
WO (1) WO2007110339A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20081477A1 (en) * 2006-12-11 2008-10-18 Hoffmann La Roche LYOPHILIZED FORMULATION MAB ABETA
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
BRPI0809112A2 (en) * 2007-03-22 2014-08-26 Imclone Llc STABLE ANTIBODY FORMULATIONS
CN101687038A (en) * 2007-07-10 2010-03-31 霍夫曼-拉罗奇有限公司 Novel formulation
CA2706403A1 (en) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Immunoglobulin aggregates
RS53551B1 (en) * 2007-12-21 2015-02-27 F. Hoffmann La Roche Ag Antibody formulation
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (en) 2009-09-11 2011-10-19 Hoffmann La Roche VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
WO2011080209A2 (en) * 2009-12-29 2011-07-07 F. Hoffmann-La Roche Ag Novel antibody formulation
WO2011147921A1 (en) * 2010-05-28 2011-12-01 Novo Nordisk A/S Stable multi-dose compositions comprising an antibody and a preservative
HUE039209T2 (en) 2011-03-31 2018-12-28 Merck Sharp & Dohme Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
CN102363040B (en) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 Antimicrobial peptide preparation for mucosal tissues
UA118029C2 (en) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Human fcrn-binding modified antibodies and methods of use
CN103505729B (en) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 A kind of stable rabies virus human antibody combination preparation
CN104707146B (en) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 A kind of pharmaceutical composition containing adalimumab
EP3094648A1 (en) 2014-01-15 2016-11-23 F. Hoffmann-La Roche AG Fc-region variants with improved protein a-binding
EP3148568A4 (en) * 2014-05-28 2018-01-17 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
AR102198A1 (en) 2014-10-09 2017-02-08 Regeneron Pharma PROCESS TO REDUCE SUBVISIBLE PARTICLES IN A PHARMACEUTICAL FORMULATION
CA2985718A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
RU2731418C2 (en) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Stable pharmaceutical preparation based on the pd-1 antibody and its use in medicine
PE20231655A1 (en) 2015-10-02 2023-10-17 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST HUMAN CD20 AND THE HUMAN TRANSFERRIN RECEPTOR AND METHODS OF USE
AR106189A1 (en) 2015-10-02 2017-12-20 Hoffmann La Roche BIESPECTIFIC ANTIBODIES AGAINST HUMAN A-b AND THE HUMAN TRANSFERRINE RECEIVER AND METHODS OF USE
CN106199007B (en) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 Protein protective agent
AU2017312785A1 (en) 2016-08-16 2019-01-24 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
EP4071469A3 (en) 2016-10-25 2022-12-14 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
JOP20190260A1 (en) 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CN110913906A (en) 2017-05-02 2020-03-24 默沙东公司 Formulations of anti-LAG 3 antibodies and co-formulations of anti-LAG 3 antibodies with anti-PD-1 antibodies
CA3073935A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
EA202190163A1 (en) 2018-07-02 2021-03-30 Ридженерон Фармасьютикалз, Инк. SYSTEMS AND METHODS FOR PRODUCING POLYPEPTIDE FROM MIXTURE
CN114324882B (en) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 Protein stabilizer and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
PE20020801A1 (en) * 2001-01-05 2002-09-06 Pfizer ANTIBODIES AGAINST INSULIN-LIKE GROWTH FACTOR RECEPTOR
MXPA04000747A (en) * 2001-07-25 2004-07-08 Protein Desing Labs Inc Stable lyophilized pharmaceutical formulation of igg antibodies.
US7378503B2 (en) * 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
AU2004229335C1 (en) * 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
KR100825156B1 (en) * 2003-08-13 2008-04-24 화이자 프로덕츠 인코포레이티드 - modified human igf-ir antibodies

Also Published As

Publication number Publication date
EP1998806A1 (en) 2008-12-10
TW200815029A (en) 2008-04-01
WO2007110339A1 (en) 2007-10-04
AR060130A1 (en) 2008-05-28
IL193904A0 (en) 2011-08-01
JP2009531371A (en) 2009-09-03
RU2008142359A (en) 2010-05-10
KR20080104160A (en) 2008-12-01
AU2007229554A1 (en) 2007-10-04
CA2647111A1 (en) 2007-10-04
ECSP088778A (en) 2008-10-31
CN101410137A (en) 2009-04-15
NO20083895L (en) 2008-10-24
MX2008012295A (en) 2008-10-09
CR10295A (en) 2008-10-06
CL2007000797A1 (en) 2008-01-25
BRPI0709229A2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
MA30345B1 (en) ANTI-IGF-1R HUMAN MONOCLONAL ANTIBODY FORMULATION
MA31984B1 (en) Formulation of antibodies
MA29369B1 (en) FIXED ASSAY OF ANTI-HER ANTIBODIES
MA30497B1 (en) ANTIBODIES AND IMMUNO-CONJUGATES, AND THEIR USES.
FR23C1029I2 (en) ANTI-CTLA-4 ANTIBODY COMPOSITIONS
MA31502B1 (en) Antibodies antibodies-notch specific NRR and methods of use.
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
MA32099B1 (en) Composition comprising an antibody binding to her2 domain ii and acidic variants thereof
MA33198B1 (en) ANTI-HER DI-SPECIFIC ANTIBODIES
MA30353B1 (en) ANTIBODIES BINDING HUMAN BETA TYROSINE PHOSPHATASE PROTEIN (HPTPBETA) AND USES THEREOF.
MA31231B1 (en) Antibodies and anti-robo4 antibodies and their uses.
MA30910B1 (en) ANTIBODIES AND IMMUNOCONJUGATES, AND USES THEREOF
MA30945B1 (en) ANTI-TAT226 AND IMMUNOCONJUGATED ANTIBODIES
MA34524B1 (en) ANTIBODIES FOR EPIDERMAL GROWTH FACTOR RECEPTOR 3 (HER3)
EA200601670A1 (en) Conjugates of hydroxyalkyl starch and protein
UA92505C2 (en) Anti-cd3 antibody formulations
BR0208338A (en) Pyridine Derivatives
BR0316670A (en) Chimeric and humanized integrin (alpha) 5ß1 antibodies that modulate angiogenesis
MA50752A (en) ANTI-CD71 ACTIVABLE ANTIBODY DRUG CONJUGATES AND METHODS OF USE
BRPI0509184A (en) pharmaceutical compositions
MA33537B1 (en) Antibodies against human cdcp1
MA30474B1 (en) FORMULATIONS OF MOLECULE PEPTIDE (S) - LYOPHILIZED THERAPEUTIC ANTIBODY.
AR058085A1 (en) DIHYDROGEN SALT PHOSPHATE OF AN ANTAGONIST OF PROSTAGLANDINA RECEIVER D2. PHARMACEUTICAL COMPOSITIONS.
HK1071586A1 (en) Transplant acceptance inducing cells of monocytic origin and their preparation and use
DK1694706T3 (en) Modified anti-CD52 antibody